1 / 37

TIES F2F 2016 Augusta University

Discover the innovative Georgia Cancer Center and its leading role in Cancer Immunology, Molecular Oncology, and Tumor Angiogenesis through the AU Biorepository. Meet the dedicated team driving breakthroughs in cancer treatments. Learn about research areas, challenges, governance, and efforts to redefine personalized medicine.

byard
Download Presentation

TIES F2F 2016 Augusta University

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TIES F2F 2016Augusta University • November 4, 2016

  2. Who is AU? • MCG (1833–2011) • GHSU (2011–2013) • 2013: Georgia Regents University= GHSU + ASU

  3. Now AU

  4. Founded in 1828 • 13th -oldest medical school • 8th -largest medical school • Nine Colleges • 9000 students (across campuses 240 medical students/year) • Supporting GR Health System • 478-bed AU Health Medical Center • 154-bed Children's Hospital of Georgia

  5. Georgia Cancer Center • The Georgia Cancer Center has three expressions, one laboratory-based, one clinic-based and one education-based. • Our research facilities celebrate innovation, combining form with function to offer our scientists an environment for collaboration and discovery.

  6. GCC Areas of Research Focus Cancer Immunology, Inflammation and Tolerance Cancer Prevention & Control Molecular Oncology & Biomarkers Tumor Signaling & Angiogenesis

  7. Our Team Repository Side: • Sameera Qureshi – Biorepository Lab Associate • Rahil Khan – Biorepository Lab Assistant • Lelyand Stone – Biorepository Lab Assistant • Denise Harper – Biorepository Study Coordinator • Roni Bollag –Biorepository Director • Nita Maihle – Associate Director, TIES Liaison Our Team

  8. Our Team (con’t) IT Side: • Mia Jolly – Business Analyst/Project Coordinator • Pankhil Patel – DBA • Colleen Cain – Director Enterprise Application Systems • Charles Busbee – Manager, Database & Application Administration • Michael Casdorph – Associate VP Academic & Research Technology

  9. The AU Biorepository: Tumor Bank: • Provides MCG researchers access to high quality, annotated specimens, to support basic and clinical cancer research • Shared resource for the Cancer Center, important for its NCI designation process (P30 grant) BRAG-Onc: • Serves as coordinating hub and central repository for the statewide repository network

  10. TCRN Challenges • EHR = Cerner Millenium / Pathnet (switched from Copath in 2005) • Biorepository Database: TissueMetrix • Mostly non-functional for translational research applications • Soon to convert to LabVantage • Clinical Trials Database: Oncore

  11. AU Pathology • 12 - 14,000 surgical specimens/year • Since 2000 (target for retrospective data capture) – 255,000 reports • MCG surgical emphases: endocrine oncology, urologic oncology, gynecological oncology

  12. Safe Harbor at GRU • DeID software package licensed (Y3) from DeIData systems implemented to generate over 200,000 reports with scrubbed identifiers • QI plan completed; current documentation in RedCap

  13. Compliance at AU • obtained IRB sanction of TIES consortium aggregate data to be designated as non-human subjects research • IRB renewal for TIES project has been ongoing • Working with IRB to include TIES in model to procure surgical pathology cases

  14. IRB Continuing Review

  15. Governance at GRU • Creation of GRU TIES project approval committee to evaluate external and internal TIES project submissions, in conformance with TCRN governance mandate. • Natasha Savage • Nita Maihle • Roni Bollag

  16. [This slide intentionally left blank]

  17. Total Reports to-date 209,676 reports Report Types • Autopsy • Surgical • Bone marrow • Cytology (likely superfluous)

  18. IT support at AU • Export of retrospective surgical pathology reports from Cerner Pathnet into firewall-protected honest brokerage archive via HL7 pipeline • Feed-forward pipeline for download of current surgical pathology reports • Some problems due to interim reports double-reported • Solved seamlessly by Girish Chavan

  19. Dissemination

  20. Current Users at AU • Only 10 with active accounts • Need to recruit more devotees to TIES • Face-to-face discussions sometimes lead to ambiguity • Need to proselytize with regards to TIES : • Developing IRB protocol to include TIES documentation to support sample release • Cancer Center is migrating more to a self-directed case identification model • Integration of TIES with biorepository archive would make major improvement in biorepository service model

  21. Efforts to Date • Pathology Faculty Meetings • Core Facility Poster Session • GCC Website Advert • PRIDE symposium demo, 2015 & 2016 • IRB Protocol in Development for FFPE Accession: “An Honest Broker Protocol for Provision of FFPE materials for Research Using TIES DeidentifiedInformatics” • Face to Face with Colleagues

  22. Pilot Project:Demographic Characterization of Tenosynovial Giant Cell Tumor Roni J. Bollag, MD, PhD Suash Sharma, MD

  23. PVNS/GCT • Pigmented Villonodular Synovitis (PVNS) • Tenosynovial Giant Cell Tumor (TGCT) = Giant Cell Tumor of Tendon Sheath • Incidence ~ 600 new cases per year in US, often young adults • Clonal neoplastic process resulting in over-expression of CSF1 in synovium • Frequently due to genetic translocation: t(1;2) CSF1:COL6A3 • Propagation of neoplastic clone (autocrine) • Reactive inflammatory process with proliferation & recruitment of CSF1R-expressing cells: macrophages, giant cells, osteoclasts • Surgery is standard of care (e.g., joint replacement, amputation) • Pharmaceutical target: blockade of CSF-1 Receptor (orphan drug designation?)

  24. TCRN output for GCT • UPMC : 1190 patients • UPENN: 396 patients • RPCI: 8 patients • AU: 73 patients • Total: 1667 patients

  25. Graphic Output

  26. Spreadsheet for PVNS / GCT

  27. PVNS @ AU summary

  28. Pilot Projects in Contemplation

  29. Oligodendroglioma Prognosis • Cases with 1p / 19q deletion annotation • To be assessed for partial deletion status • Comparison between FISH and molecular annotation • [Dr. Suash Sharma]

  30. Langerhans Cell Histiocytosis • Langerhans Cell Histiocytosis has been proven to be a clonal disorder among a large subset of cases showing BRAF V600E mutations • A subset of cases do not harbor this mutation (mostly MAP2K and ERK-activation pathways)

  31. Langerhans Cell Histiocytosis • Identification of such mutations via NGS may further exemplify and characterize this disorder to demonstrate more universal clonality • Caveat for study: most cases have been acid-treated for decalcification – need to review for cases without decalcification

  32. Toys to Integrate into TIES • Imaging systems • Bandwidth • LabVantage Software • TMA Construction • Nucleic Acid Isolation

  33. Slide Scanning with Leica Ariol

  34. Getting geared up to use the PE Vectra system

  35. TMA Grand Master

  36. Summary • AU node is up and running: good things to come • Compliance is current from institutional perspective • Gaps in data upload – needs to be tweaked • Safe Harbor QA complete • Imaging, TMA, Computing upgrades • Pilot projects with inclusion of AU: • So far, so good…

More Related